Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, ...
Stifel lowered its price target on Klaviyo to $35 from $40 with a Buy rating. The firm noted that the company delivered a ...
Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on ...
Asianet Newsable on MSN
Figma Q4 results beat street expectations, so why are analysts slashing targets?
RBC Capital lowered its target on Figma to $31 from $38 and kept a ‘Sector Perform’ rating on the shares, according to TheFly ...
Wall Street forecasts earnings of $0.16 per share on revenue of $988 million, representing a 36% year-over-year decline in profit but a 73% surge in sales. The revenue jump reflects the addition of ...
Mikaela Shiffrin and her fiancé, Aleksander Aamodt Kilde, help each other get through the " tough moments " of being ...
When structured notes or products go wrong, broker-dealers can wind up in costly litigation. A three-person FINRA arbitration ...
The agreement, announced after the market closed on Tuesday, pushed Nvidia shares up 2.3% to $191.40 on Wednesday. The ...
Evidence of durability of psilocybin-based COMP360 is a key point for the FDA, according to Compass Pathways Chief Medical ...
WHEELING — Wheeling Central knows every opponent it plays is going to take its best shot at the undefeated Maroon Knights. Under-sized Linsly (5-13) did just that Tuesday night — for the second time ...
TheFly reported on February 5 that Stifel lowered its price target on HNGE to $59 from $66 and maintained a Buy rating on the ...
Investing.com -- Stifel on Tuesday initiated coverage of MHA plc with a “buy” rating and a target price of 205p, representing 35% potential upside from the stock’s closing price of 151.5p on Feb. 16.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results